Rigel Pharmaceuticals (RIGL) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rigel Pharmaceuticals (RIGL) has outperformed Savara (SVRA) over the past year, gaining 69.4% versus a gain of 39.2%. Over five years, SVRA leads with a +274.4% price change compared with +44.1% for RIGL. Savara is the larger company by market cap ($992.4 million vs $910.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RIGL | SVRA |
|---|---|---|
| Share price | $48.72 | $4.83 |
| Market cap | $910.08M | $992.37M |
| 1-day change | +1.52% | -1.02% |
| YTD return | +13.75% | -19.90% |
| 1-year return | +69.40% | +39.19% |
| 5-year return | +44.14% | +274.42% |
| P/E ratio (TTM) | 2.89 | — |
| Forward P/E | 9.86 | — |
| EPS (TTM) | $16.88 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.24 | $7.01 |
| 52-week low | $24.95 | $3.35 |
| Distance from 52-week high | -6.74% | -31.05% |
| Analyst consensus | none | none |
| Avg. price target upside | +29.31% | +128.99% |
| Average volume | 289.05K | 1.83M |
| Shares outstanding | 18.68M | 205.46M |
| Employees | 172 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RIGL has outperformed SVRA by 30.2 percentage points over the past year.
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
RIGL vs SVRA FAQ
Which is bigger, Rigel Pharmaceuticals or Savara?
Savara (SVRA) is larger, with a market capitalization of $992.37M compared with $910.08M for Rigel Pharmaceuticals (RIGL).
Which stock has performed better over the past year, RIGL or SVRA?
RIGL returned +69.40% over the past 12 months, compared with +39.19% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are Rigel Pharmaceuticals and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.